摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-amino-2-methyl-4-(4-hydroxyphenyl)butane hydrochloride

中文名称
——
中文别名
——
英文名称
2-amino-2-methyl-4-(4-hydroxyphenyl)butane hydrochloride
英文别名
4-(3-Amino-3-methylbutyl)phenol hydrochloride;4-(3-amino-3-methylbutyl)phenol;hydrochloride
2-amino-2-methyl-4-(4-hydroxyphenyl)butane hydrochloride化学式
CAS
——
化学式
C11H17NO*ClH
mdl
——
分子量
215.723
InChiKey
IWWRZHZMHLKVMZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.48
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    46.2
  • 氢给体数:
    3
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • Pyridyl aminoethanol compounds with growth promotion and an increase in
    申请人:Merck & Co., Inc.
    公开号:US04906645A1
    公开(公告)日:1990-03-06
    There are disclosed six pyridyl aminoethanol substituted on the amine with a substituted phenylalkyl group. The compounds are highly potent growth promotion agents for animals and compositions for such uses are also disclosed.
    揭示了六种在胺上以取代苯基烷基为取代基的吡啶基氨基乙醇。这些化合物是动物高效的生长促进剂,并且还揭示了用于这种用途的组合物。
  • Selective &bgr;3 adrenergic agonists
    申请人:Eli Lilly and Company
    公开号:US06617347B1
    公开(公告)日:2003-09-09
    The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of the Formula I: or pharmaceutically acceptable salts thereof.
    本发明属于医学领域,特别是用于治疗II型糖尿病和肥胖症。更具体地说,本发明涉及有选择性的β3受体激动剂,可用于治疗II型糖尿病和肥胖症。本发明提供了化合物和治疗II型糖尿病和肥胖症的方法,包括向需要的哺乳动物中给予公式I的化合物或其药学上可接受的盐。
  • Pyridyl aminoethanols with animal growth promotion activity and a high degree of safety
    申请人:Merck & Co., Inc.
    公开号:EP0359313A1
    公开(公告)日:1990-03-21
    There are disclosed six pyridyl aminoethanol substituted on the amine with a substituted phenylalkyl group. The compounds are highly potent growth promotion agents for animals and compositions for such uses are also disclosed.
    本发明公开了六个在胺上被取代的苯基烷基取代的吡啶基氨基乙醇。这些化合物是高效的动物生长促进剂,还公开了用于这种用途的组合物。
  • Selective beta 3 adrenergic agonists
    申请人:ELI LILLY AND COMPANY
    公开号:EP0921120A1
    公开(公告)日:1999-06-09
    The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective b3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of the Formula I: wherein: X1 is -OCH2-, -SCH2-, or a bond; R1 is a heterocycle of the formula: R2 and R3 are independently hydrogen, C1-C4 alkyl, or aryl; R4 is an optionally substituted heterocycle or a moiety selected from the group consisting of: X2 is a bond, or a 1 to 5 carbon straight or branched alkylene; R5 is hydrogen or C1-C4 alkyl; R6 is hydrogen or C1-C4 alkyl; or R5 and R6 combine with the carbon to which each is attached to form a C3-C6 cycloalkyl; or R6 combines with X2 and the carbon to which each is attached to form a C3-C8 cycloalkyl; or R6 combines with X2, R4, and the carbon to which each is attached to form: provided that R5 is hydrogen; R7 is hydrogen, hydroxy, cyano, oxo, COnR2, CONHR2, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 optionally substituted alkyl, (CH2)n aryl, (CH2)nheterocycle, (CH2)n optionally substituted aryl, or (CH2)n optionally substituted heterocycle; R8 is independently hydrogen, halo, or C1-C4 alkyl; R9 is halo, CN, OR10, C1-C4 alkyl, C1-C4 haloalkyl, CO2R2, CONR11R12, CONH(C1-C4 alkyl or C1-C4 alkoxy), SR2, CSNHR2, CSNR11R12, SO2R2, SOR2, NR11R12, optionally substituted aryl, optionally substituted heterocycle, or C2-C4 alkenyl substituted with CN, CO2R2, or CONR11R12; R10 is C1-C4 alkyl, C1-C4 haloalkyl, (CH2)nC3-C8 cycloalkyl, (CH2)naryl, (CH2)nheterocycle, (CH2)nC3-C8 optionally substituted cycloalkyl, (CH2)n optionally substituted aryl, or (CH2)n optionally substituted heterocycle; R11 and R12 are independently hydrogen, C1-C4 alkyl, aryl, (CH2)naryl, or combine with the nitrogen to which each is bound to form morpholinyl, piperidinyl, pyrrolidinyl, or piperazinyl; R13 is hydrogen, halo, aryl, or C1-C4 alkyl; m is 0 or 1; n is 0, 1, 2, or 3; or a pharmaceutically acceptable salt thereof.
    本发明属于医学领域,特别是 II 型糖尿病和肥胖症的治疗。更具体地说,本发明涉及用于治疗 II 型糖尿病和肥胖症的选择性 b3 受体激动剂。本发明提供了治疗 II 型糖尿病和肥胖症的化合物和方法,包括向需要的哺乳动物施用式 I 的化合物: 其中 X1是-OCH2-、-SCH2-或键; R1 是式中的杂环: R2 和 R3 独立地为氢、C1-C4 烷基或芳基; R4 是任选取代的杂环或选自以下组成的组的分子: X2 是键,或 1 至 5 碳直链或支链亚烷基; R5 是氢或 C1-C4 烷基 R6 是氢或 C1-C4 烷基; 或 R5 和 R6 与各自相连的碳结合形成 C3-C6 环烷基; 或 R6 与 X2 和各自相连的碳结合形成 C3-C8 环烷基; 或 R6 与 X2、R4 和各自相连的碳结合形成: 但 R5 为氢; R7 是氢、羟基、氰基、氧代、COnR2、CONHR2、C1-C4 烷基、C1-C4 烷氧基、C1-C4 卤代烷基、C1-C4 任选取代的烷基、(CH2)n 芳基、(CH2)n 杂环、(CH2)n 任选取代的芳基或 (CH2)n 任选取代的杂环; R8 独立地为氢、卤代或 C1-C4 烷基; R9 是卤素、CN、OR10、C1-C4 烷基、C1-C4 卤代烷基、CO2R2、CONR11R12、CONH(C1-C4 烷基或 C1-C4 烷氧基)、SR2、CSNHR2、CSNR11R12、SO2R2、SOR2、NR11R12、任选取代的芳基、任选取代的杂环或被 CN、CO2R2 或 CONR11R12 取代的 C2-C4 烯基; R10 是 C1-C4 烷基、C1-C4 卤代烷基、(CH2)nC3-C8 环烷基、(CH2)n 芳基、(CH2)n 异环、(CH2)nC3-C8 任选取代的环烷基、(CH2)n 任选取代的芳基或 (CH2)n 任选取代的杂环; R11 和 R12 独立地为氢、C1-C4 烷基、芳基、(CH2)芳烷基,或与各自结合的氮结合形成吗啉基、哌啶基、吡咯烷基或哌嗪基; R13 是氢、卤代、芳基或 C1-C4 烷基; m 是 0 或 1; n 是 0、1、2 或 3; 或其药学上可接受的盐。
  • US4906645A
    申请人:——
    公开号:US4906645A
    公开(公告)日:1990-03-06
查看更多